← 產業報告目錄
CIN and HR-HPV Treatment Market Size, Share & Trends Analysis Report By Disease Type (Cervical Intraepithelial Neoplasia 1, Cervical Intraepithelial Neoplasia 2, and Cervical Intraepithelial Neoplasia 3), Strain Type (HPV 16, HPV 18, and Others), Offering, Product Type, and End User, Region And Segment Forecasts, 2023-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-12頁數 180報告編號 INSIGHTACE-bca0813a93
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
With a 2022 valuation of USD 11.48 billion, the global CIN and HR-HPV Treatment Market is expected to accelerate to USD 20.08 billion by 2031, demonstrating a CAGR of 6.5% during the 2023–2031 forecast window.
CIN and HR-HPV Treatment encompasses a key risk factor for cervical intraepithelial neoplasia and a sexually transmitted disease. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Market momentum is underpinned by growing interest in advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region expected to deliver the strongest growth trajectory through the forecast period, underpinned by demographic shifts and policy support.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global CIN and HR-HPV Treatment Market Snapshot
Chapter 4. Global CIN and HR-HPV Treatment Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Product Type Estimates & Trend Analysis
5.1. By Product Type, & Market Share, 2020 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Product Type:
5.2.1. Kits & Reagents
5.2.2. Instruments
5.2.3. Services
Chapter 6. Market Segmentation 2: By Strain Type Estimates & Trend Analysis
6.1. By Strain Type & Market Share, 2020 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Strain Type:
6.2.1. HPV 16
6.2.2. HPV 18
6.2.3. Others
Chapter 7. Market Segmentation 3: By Offering Estimates & Trend Analysis
7.1. By Offering & Market Share, 2020 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Offering:
7.2.1. Diagnostic Method
7.2.2. Treatment
Chapter 8. Market Segmentation 4: By End user Estimates & Trend Analysis
8.1. By End user & Market Share, 2020 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By End user:
8.2.1. Hospitals & Clinics
8.2.2. Diagnostic Laboratories
8.2.3. Specialized Clinical Laboratories
8.2.4. Others
Chapter 9. Market Segmentation 5: By Disease Type Estimates & Trend Analysis
9.1. By Disease Type & Market Share, 2020 & 2031
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Disease Type:
9.2.1. Cervical Intraepithelial Neoplasia 1
9.2.2. Cervical Intraepithelial Neoplasia 2
9.2.3. Cervical Intraepithelial Neoplasia 3
Chapter 10. CIN and HR-HPV Treatment Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. North America
10.1.1. North America CIN and HR-HPV Treatment Market revenue (US$ Million) estimates and forecasts By Product Type, 2019-2031
10.1.2. North America CIN and HR-HPV Treatment Market revenue (US$ Million) estimates and forecasts By Strain Type, 2019-2031
10.1.3. North America CIN and HR-HPV Treatment Market revenue (US$ Million) estimates and forecasts By Offering, 2019-2031
10.1.4. North America CIN and HR-HPV Treatment Market revenue (US$ Million) estimates and forecasts By End user, 2019-2031
10.1.5. North America CIN and HR-HPV Treatment Market revenue (US$ Million) estimates and forecasts By Disease Type, 2019-2031
10.1.6. North America CIN and HR-HPV Treatment Market revenue (US$ Million) estimates and forecasts by country, 2019-2031
10.2. Europe
10.2.1. Europe CIN and HR-HPV Treatment Market revenue (US$ Million) By Product Type, 2019-2031
10.2.2. Europe CIN and HR-HPV Treatment Market revenue (US$ Million) By Strain Type, 2019-2031
10.2.3. Europe CIN and HR-HPV Treatment Market revenue (US$ Million) By Offering, 2019-2031
10.2.4. Europe CIN and HR-HPV Treatment Market revenue (US$ Million) By End user, 2019-2031
10.2.5. Europe CIN and HR-HPV Treatment Market revenue (US$ Million) By Disease Type, 2019-2031
10.2.6. Europe CIN and HR-HPV Treatment Market revenue (US$ Million) by country, 2019-2031
10.3. Asia Pacific
10.3.1. Asia Pacific CIN and HR-HPV Treatment Market revenue (US$ Million) By Product Type, 2019-2031
10.3.2. Asia Pacific CIN and HR-HPV Treatment Market revenue (US$ Million) By Strain Type, 2019-2031
10.3.3. Asia Pacific CIN and HR-HPV Treatment Market revenue (US$ Million) By Offering, 2019-2031
10.3.4. Asia Pacific CIN and HR-HPV Treatment Market revenue (US$ Million) By End user, 2019-2031
10.3.5. Asia Pacific CIN and HR-HPV Treatment Market revenue (US$ Million) By Disease Type, 2019-2031
10.3.6. Asia Pacific CIN and HR-HPV Treatment Market revenue (US$ Million) by country, 2019-2031
10.4. Latin America
10.4.1. Latin America CIN and HR-HPV Treatment Market revenue (US$ Million) By Product Type, (US$ Million) 2019-2031
10.4.2. Latin America CIN and HR-HPV Treatment Market revenue (US$ Million) By Strain Type, (US$ Million) 2019-2031
10.4.3. Latin America CIN and HR-HPV Treatment Market revenue (US$ Million) By Offering, (US$ Million) 2019-2031
10.4.4. Latin America CIN and HR-HPV Treatment Market revenue (US$ Million) By End user, (US$ Million) 2019-2031
10.4.5. Latin America CIN and HR-HPV Treatment Market revenue (US$ Million) By Disease Type, (US$ Million) 2019-2031
10.4.6. Latin America CIN and HR-HPV Treatment Market revenue (US$ Million) by country, 2019-2031
10.5. Middle East & Africa
10.5.1. Middle East & Africa CIN and HR-HPV Treatment Market revenue (US$ Million) By Product Type, (US$ Million) 2019-2031
10.5.2. Middle East & Africa CIN and HR-HPV Treatment Market revenue (US$ Million) By Strain Type, (US$ Million) 2019-2031
10.5.3. Middle East & Africa CIN and HR-HPV Treatment Market revenue (US$ Million) By Offering, (US$ Million) 2019-2031
10.5.4. Middle East & Africa CIN and HR-HPV Treatment Market revenue (US$ Million) By End user, (US$ Million) 2019-2031
10.5.5. Middle East & Africa CIN and HR-HPV Treatment Market revenue (US$ Million) By Disease Type, (US$ Million) 2019-2031
10.5.6. Middle East & Africa CIN and HR-HPV Treatment Market revenue (US$ Million) by country, 2019-2031
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Fujirebio Europe NV
11.2.2. Qiagen NV
11.2.3. Zilico Ltd
11.2.4. Abbott Laboratories
11.2.5. Cepheid
11.2.6. F. Hoffmann-La Roche Ltd
11.2.7. INOVIO Pharmaceuticals Inc
11.2.8. Bioneer Corp
11.2.9. Antiva Biosciences Inc
11.2.10. Thermo Fisher Scientific Inc.
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們